Monitoring patients with celiac disease on gluten free diet : different outcomes comparing three tissue transglutaminase IgA assays
© 2023 Walter de Gruyter GmbH, Berlin/Boston..
OBJECTIVES: Tissue transglutaminase (tTG) IgA antibodies are a hallmark for celiac disease (CD). In CD patients on gluten free diet (GFD) these antibodies are transient. Few studies are available comparing the tTG-IgA assay characteristics for monitoring response to GFD. Since discrepant results were reported in patients on GFD after switching tTG-IgA assays, we conducted a retrospective observational study to monitor GFD response using three different tTG-IgA assays.
METHODS: Diagnostic samples from 44 adults and 17 children with CD were included. Of most patients two follow-up samples after introduction of GFD were available. In all samples tTG-IgA were assessed using one fluorochrome-enzyme immuno-assay (FEIA) and two chemiluminescence immuno-assays (CLIA) and intestinal fatty acid binding protein (i-FABP) as surrogate marker for intestinal epithelial damage was measured.
RESULTS: Using CLIA assays, normalization of antibody levels was delayed compared to FEIA (p<0.001). Of all samples taken after at least 6 months on GFD with elevated i-FABP indicating intestinal epithelial damage, 40 % had positive tTG-IgA according to the FEIA, 85 and 90 % according to the two CLIA.
CONCLUSIONS: Normalization of tTG-IgA in patients on GFD depends on the assay used. Both CLIA appear to be more sensitive in detecting suboptimal treatment response in CD-indicated by elevated i-FABP - when applying the manufacturer's recommended cut-off for the diagnosis of CD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:62 |
|---|---|
| Enthalten in: |
Clinical chemistry and laboratory medicine - 62(2024), 4 vom: 25. Feb., Seite 674-681 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mulder, A H Leontine [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 27.02.2024 Date Revised 27.02.2024 published: Electronic-Print Citation Status MEDLINE |
|---|
| doi: |
10.1515/cclm-2023-1076 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364348283 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364348283 | ||
| 003 | DE-627 | ||
| 005 | 20240229163733.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1515/cclm-2023-1076 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1308.xml |
| 035 | |a (DE-627)NLM364348283 | ||
| 035 | |a (NLM)37943101 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mulder, A H Leontine |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Monitoring patients with celiac disease on gluten free diet |b different outcomes comparing three tissue transglutaminase IgA assays |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.02.2024 | ||
| 500 | |a Date Revised 27.02.2024 | ||
| 500 | |a published: Electronic-Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 Walter de Gruyter GmbH, Berlin/Boston. | ||
| 520 | |a OBJECTIVES: Tissue transglutaminase (tTG) IgA antibodies are a hallmark for celiac disease (CD). In CD patients on gluten free diet (GFD) these antibodies are transient. Few studies are available comparing the tTG-IgA assay characteristics for monitoring response to GFD. Since discrepant results were reported in patients on GFD after switching tTG-IgA assays, we conducted a retrospective observational study to monitor GFD response using three different tTG-IgA assays | ||
| 520 | |a METHODS: Diagnostic samples from 44 adults and 17 children with CD were included. Of most patients two follow-up samples after introduction of GFD were available. In all samples tTG-IgA were assessed using one fluorochrome-enzyme immuno-assay (FEIA) and two chemiluminescence immuno-assays (CLIA) and intestinal fatty acid binding protein (i-FABP) as surrogate marker for intestinal epithelial damage was measured | ||
| 520 | |a RESULTS: Using CLIA assays, normalization of antibody levels was delayed compared to FEIA (p<0.001). Of all samples taken after at least 6 months on GFD with elevated i-FABP indicating intestinal epithelial damage, 40 % had positive tTG-IgA according to the FEIA, 85 and 90 % according to the two CLIA | ||
| 520 | |a CONCLUSIONS: Normalization of tTG-IgA in patients on GFD depends on the assay used. Both CLIA appear to be more sensitive in detecting suboptimal treatment response in CD-indicated by elevated i-FABP - when applying the manufacturer's recommended cut-off for the diagnosis of CD | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a celiac disease | |
| 650 | 4 | |a intestinal fatty acid binding protein (i-FABP) | |
| 650 | 4 | |a monitoring gluten free diet response | |
| 650 | 4 | |a tissue transglutaminase (tTG)-IgA | |
| 650 | 7 | |a Protein Glutamine gamma Glutamyltransferase 2 |2 NLM | |
| 650 | 7 | |a EC 2.3.2.13 |2 NLM | |
| 650 | 7 | |a Transglutaminases |2 NLM | |
| 650 | 7 | |a EC 2.3.2.13 |2 NLM | |
| 650 | 7 | |a Autoantibodies |2 NLM | |
| 650 | 7 | |a Immunoglobulin A |2 NLM | |
| 700 | 1 | |a Castelijn, Daan A R |e verfasserin |4 aut | |
| 700 | 1 | |a van der Pol, Pieter |e verfasserin |4 aut | |
| 700 | 1 | |a Vermeer, Marloes |e verfasserin |4 aut | |
| 700 | 1 | |a Hollander, Jolien C |e verfasserin |4 aut | |
| 700 | 1 | |a Kuiper, Tietie |e verfasserin |4 aut | |
| 700 | 1 | |a Bijnens, Caroline |e verfasserin |4 aut | |
| 700 | 1 | |a Bontkes, Hetty J |e verfasserin |4 aut | |
| 700 | 1 | |a Damoiseaux, Jan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical chemistry and laboratory medicine |d 1998 |g 62(2024), 4 vom: 25. Feb., Seite 674-681 |w (DE-627)NLM095304118 |x 1437-4331 |7 nnns |
| 773 | 1 | 8 | |g volume:62 |g year:2024 |g number:4 |g day:25 |g month:02 |g pages:674-681 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1515/cclm-2023-1076 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 62 |j 2024 |e 4 |b 25 |c 02 |h 674-681 | ||